Quantification of Binding and Neutralizing Antibody Levels in COVID-19 Vaccinated Health Care Workers Over 1 Year

NCT04910971 | Unknown

• 1 other identifier: 1707882
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic presents a great challenge to global health. The first case was identified in December 2019 in Wuhan, China and since has infected nearly 100 million people and claimed almost 2 million lives worldwide. In response, the medical community and scientists have worked hard to develop effective therapies and guidelines to treat a wide range of symptoms including the use of the antiviral drug remdesivir, convalescent plasma, antibiotics, steroids, and anticoagulant therapy. To prevent the spread of the disease, multiple vaccines based on mRNA and DNA technologies that include inactivated viral components have been developed and millions of doses are currently being administered worldwide. Early analysis of data from the phase III Pfizer/BioNTech and Moderna vaccine trials suggested the vaccine was more than 90% effective in preventing the illness with a good safety profile (Polack et al., 2020). However, there are still many unknowns regarding the long-term safety of these newer vaccine technologies and the level and duration of immunogenicity. SARS-CoV-2 infection results in seroconversion and production of anti-SARS-CoV-2 antibodies. The antibodies may suppress viral replication through neutralization but might also participate in COVID-19 pathogenesis through a process termed antibody-dependent enhancement (Lu et al., 2020). Rapid progress has been made in the research of antibody response and therapy in COVID-19 patients, including characterization of the clinical features of antibody responses in different populations infected by SARS-CoV-2, treatment of COVID-19 patients with convalescent plasma and intravenous immunoglobin products, isolation and characterization of a large panel of monoclonal neutralizing antibodies and early clinical testing, as well as clinical results from several COVID-19 vaccine candidates. In this study, we plan to assess the effic of both vaccines on the healthcare workers. As healthcare workers begin to receive their first vaccination dosage, we will start looking for traces of antibodies within the blood and saliva. The data provided will help us determine the efficacy of the vaccine over a period of 1 year, identify any difference in efficacy amongst different populations (gender, age, and ethnicities) differences among vaccine types, demographics and follow-up on any potential side effects. We will collaborate with Nirmidas Biotech Inc. based in Palto Alto, California, a Stanford University spinoff on this project. Nirmidas Biotech. Inc is a young diagnostic company that have received several FDA EUA tests for COVID-19. We will perform IgG/IgM antibody detection by the NIRMIDAS MidaSpot™ COVID-19 Antibody Combo Detection Kit approved by FDA EUA for POC testing in our hospital site for qualitative antibody testing. We will then send dry blood spot and saliva to Nirmidas for the pGOLD™ COVID-19 High Accuracy IgG/IgM Assay to quantify antibody levels and avidity, both of which are important to immunity. The pGOLD assay is a novel nanotechnology assay platform capable of quantifying antibody levels and binding affinity to viruses. We collaborated recently with Nirmidas on this platform and published a joint paper in Nature Biomedical Engineering on COVID-19 Ab pGOLD assay (Liu et al., 2020). It is also capable of detecting antibodies in saliva samples and could offer a non-invasive approach to assessing antibody response for vaccination.

Conditions

COVID-19 Vaccine; Corona Virus Infection; Vaccine Adverse Reaction; Vaccine Response; Inflammation; Thrombosis

Keywords

Thrombosis; Inflammation; Vaccination; COVID-19

Outcome Measures

Primary Outcomes (2)

• Presence of IgG and IgM antibodies to SARS-CoV-2 in response to vaccination

  Detection and quantification of IgG and IgM antibodies to SARS-CoV-2 by the antibody-avidity assay test

  3 months

• Loss of IgG and IgM antibodies to SARS-CoV-2

  Loss of IgG and IgM antibodies to SARS-CoV-2 when tested by the antibody-avidity assay test and rapid COVID-19 Antibody Combo Detection Kit at days 0, 20, 45, 70, 3 months, 6 months, 9 months, 12 months post-vaccination, after initial detection of antibodies

  12 months

Secondary Outcomes (3)

• Thrombo-inflammatory syndrome

  12 months

• Side effects

  12 months

• Hypercoagulability

  12 months

Study Arms (2)

Group 1: Recipients of BNT162b2 mRNA Covid-19 Vaccine

Group 2: Recipients of mRNA-1273 SARS-CoV-2 Vaccine

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Health care workers within a large health care system being administered FDA approved SARS-CoV-2 vaccinations

You may qualify if:

• Adult males or females aged 18 years and older (inclusive) at screening.
• Able and willing (in the investigator's opinion) to comply with all study requirements.
• Willing to discuss their relevant medical history with the study investigators.
• Willing and able to give informed consent prior to study enrollment.

You may not qualify if:

• History of a recent or previous COVID-19 infection per history or as detected by either the PGOLD™COVID-19 IGG/IGM ASSAY or MidaSpot™ COVID-19 Antibody fingerstick test.

Sponsors & Collaborators

• LifeBridge Health: lead

Study Sites (1)

Sinai Hospital

Baltimore, Maryland, 21215, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Urine for urinary 11-dehdro thromboxane Blood for platelet fibrin-clot strength as measured by Thrombelastography, IgG and IgM antibodies to SARS-CoV-2

MeSH Terms

Conditions

Coronavirus Infections; Inflammation; Thrombosis; COVID-19

Condition Hierarchy (Ancestors)

Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Kevin Bliden, MBA

  Sinai Center for Thrombosis Research

  STUDY DIRECTOR

Central Study Contacts

Paul A. Gurbel, MD

CONTACT

410-601-5475; pgurbel@lifebridgehealth.org

Kevin Bliden, MBA

CONTACT

410-601-5475; kbliden@lifebridgehealth.org

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: June 1, 2021
• First Posted: June 2, 2021
• Study Start: January 31, 2021
• Primary Completion: May 28, 2022
• Study Completion: July 28, 2022
• Last Updated: June 2, 2021

Record last verified: 2021-06

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)